NASHVILLE, Tenn., Jan. 26, 2017 -- Truxton Corporation (OTCPK:TRUX), a financial holding company and the parent of Truxton Trust Company, announced that its Board of Directors has approved a quarterly cash dividend of $0.20 per common share payable March 29, 2016 to shareholders of record as of March 8, 2017.
Truxton Corporation has previously paid dividends on a semi-annual basis and in 2016 paid aggregate dividends of $0.72 per share. Annualized, today’s dividend represents an 11% increase over the 2016 dividend. This represents the fifth consecutive year of increased dividends at Truxton Corporation. President and CFO Andrew L. May said, “Our high returns on equity and measured balance sheet growth allow Truxton to return significant amounts of capital to shareholders through dividends. Our Board has also previously authorized a $1 million share repurchase, as yet unexecuted, creating another avenue to return capital.”
About Truxton Trust
Truxton Trust is a full-service private bank and trust company founded in 2004. Since its inception, Truxton Trust has been focused on a singular guiding principle: do the right thing. Truxton Trust delivers the highest level of personal service through its vastly experienced and credentialed team of professionals who provide comprehensive and customized financial solutions to individuals, their families and their business interests.
Investor Relations Andrew May 615-515-1707 [email protected] Media Relations Tamara Schoeplein 615-515-1714 [email protected]


7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 



